Use este identificador para citar ou linkar para este item: http://higia.imip.org.br/handle/123456789/1049
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorSilva, Cassiano Augusto-
dc.contributor.authorRibeiro, Marcia Gonçalves-
dc.contributor.authorSilva, Artur Quintiliano-
dc.contributor.authorGueiros, Ana Paula Santana-
dc.contributor.authorPetruccelli, Karla Cristina Silva-
dc.contributor.authorPascotto, Roberta Correa-
dc.contributor.authorBoger, Marta Vaz Dias de Souza-
dc.contributor.authorCarvalho, Luiz Roberto-
dc.contributor.authorLucca, Leandro Júnior-
dc.contributor.authorSevignani, Gabriela-
dc.contributor.authorNeto, Osvaldo Merege Vieira-
dc.contributor.authorBarretto, Carolina Teles-
dc.contributor.authorGordon, Gina Moreno-
dc.contributor.authorVeloso, Valeria Soares Pigozzi-
dc.contributor.authorVieira, Fernando Antônio Freitas-
dc.contributor.authorEnnes, Gelzie Sorrentino-
dc.contributor.authorSouza, Eduarda Morgana da Silva Montenegro Malaguti de-
dc.contributor.authorGuedes, Felipe Leite-
dc.contributor.authorBarreto, Fellype-
dc.contributor.authorAndrade, Luis Gustavo Modelli de-
dc.date.accessioned2024-06-12T17:32:39Z-
dc.date.available2024-06-12T17:32:39Z-
dc.date.issued2023-
dc.identifier.urihttp://higia.imip.org.br/handle/123456789/1049-
dc.description.abstractBackground and Aims: Fabry disease (FD) is a rare X-linked lysosomal storage disease that can affect multiple organs, including the kidneys. The main objective of this study was to evaluate the effectiveness of a combination of α-GAL enzyme activity and plasma levels of lyso-GL3 for screening FD in women with chronic kidney disease (CKD). Method: Women with CKD, stages 3 to 5, in regular nephrological follow-up were selected from renal centers in all regions of Brazil. Exclusion criteria: under 18 years old and known diagnosis of CKD. Patients underwent biochemical analysis of α-GAL enzyme activity and plasma levels of lyso-GL3. GLA gene sequencing was performed if α-GAL enzyme activity was below and/or lyso-GL3 levels were above the reference range. Sensitivity and specificity analyzes were performed to evaluate the performance of the combined biochemical approach for the diagnosis of FD. Results: From October 2020 to December 2022 1,647 collections were carried out. Low α-GAL activity was found in 44 (2.6%) of the cases and increased lyso-GL3 was found in 101 (6.1%) of the cases. The mean age was 53 [42 – 64] years. All cases of low α-GAL and/or increased lyso-GL3 were submitted to genetic analysis, and 6 positive cases were found. As for genetic variants, four patients have R118C, one A143T and other with T430G, all considered variants of uncertain significance (VUS). The sensitivity and specificity of α-GAL reduction for the detection of FD was 83.3% and 97.6%, respectively. As for the increase in lyso-GL3, the values were 16.6% and 93.9%, respectively. There were no cases that presented a concomitant increase in lyso-GL3 and a reduction in enzymatic activity. Conclusion: Preliminary results suggest that the combination of α-GAL enzymatic activity with lyso-GL3 measurement may be a good alternative for screening FD in women with CKD. A thorough medical evaluation is required to determine the pathogenicity of variants in these patients.pt_BR
dc.language.isoenpt_BR
dc.subjectDoença de Fabrypt_BR
dc.subjectSaúde da mulherpt_BR
dc.subjectNefrologiapt_BR
dc.titleAn alternative method for screening fabry disease in women: partial results of a brazilian study.pt_BR
dc.higia.programArtigos científicos colaboradores IMIPpt_BR
dc.higia.tipoArtigo Científicopt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
IMIP_Artigo - 018.2022-2023.pdf200.82 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.